Web Press Release No. 187
Download PDF version of this document.

December 1, 2005

AMRI Names Senior Director of Analytical Quality Services

Pfizer Veteran Joins Analytical Team

Albany, NY (December 1, 2005) -- Albany Molecular Research, Inc. (Nasdaq: AMRI) announced today that Steven R. Hagen, Ph.D. has joined the company as senior director of analytical quality services.

In his new role, Dr. Hagen will oversee all analytical chemistry efforts, which includes providing support for early stage discovery and preclinical development, as well as the manufacturing of clinical trial materials, intermediates, and commercial active pharmaceutical ingredients. This includes developing analytical methods to test the purity of clinical trial candidates and commercial products manufactured at AMRI. He will provide leadership to a team of over 100 skilled analytical chemists and work closely with customers.

Prior to joining AMRI, Dr. Hagen was director of analytical research and development at Pfizerís Global Research and Development Division in Kalamazoo, Michigan. In this position, he led a group of scientists responsible for supporting chemical research and development and all product stability activities. He began his tenure at Pfizer in 1994 as a research scientist and rose through the ranks to become director. Prior to Pfizer, he was an analytical biochemist with Montana-based Ribi ImmunoChem Research, Inc., where he managed the analytical activities of the company in support of R&D, production and quality control.

Dr. Hagen earned a Ph.D. in biochemistry and a Masterís in botany, both from the University of Idaho, as well as a B.A. in biology from Lawrence University. He has authored numerous publications.

Albany Molecular Research, Inc. is a global drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs.

-30-

Media Contact: David Albert, Director of Communications, Albany Molecular Research, Inc., 518-464-0279, ext. 2229

Investor Contact: P. Curtis Schenck, Investor Relations Manager, Albany Molecular Research, Inc., 518-464-0279, ext. 2933

Return to Main Press Release Page

Albany Molecular Research.
All Rights Reserved.